This page presents educational information originally published by the Tennessee Breast Center. It is general knowledge, not medical advice — read our full disclaimer.
Are you at increased risk of developing breast cancer? The National Cancer Institute has developed a breast cancer risk assessment tool that estimates your risk of developing breast cancer during the next five years and over the course of a lifetime. Click “calculate risk” for a new patient and complete the questions.
If you are at elevated risk, three options are available to help modify that risk:
| Option | What it means |
|---|---|
| 1. Increased surveillance | Important for women with a significantly positive premenopausal family history. Begin screening mammography a decade sooner than the age at which the family member was diagnosed. For example, if your mother was 35 at the time of her breast cancer diagnosis, you should begin annual screening mammography at age 25. |
| 2. Bilateral prophylactic mastectomy | Substantially reduces the risk of developing breast cancer, but does not completely eliminate it. Annual screening should continue. |
| 3. Chemoprevention | Women at increased risk can be placed on tamoxifen. The Breast Cancer Prevention Trial (BCPT), begun in 1992, compared placebo to tamoxifen and found the risk of developing breast cancer reduced by 50%. Risk factors weighed in the decision include family history, age, the number of previous breast biopsies and the pathologic findings on those biopsies. |
A second study comparing tamoxifen to raloxifene (Evista) — the STAR trial — was enrolling 22,000 postmenopausal women at the time this material was written; it was designed to compare raloxifene’s ability to prevent breast cancer with tamoxifen’s proven ability to do so.
Most patients opt for increased surveillance and/or chemoprevention with tamoxifen or raloxifene to reduce their risk.
Medical links
The following organizations publish authoritative breast health information. These links are provided for convenience and further information; they are not endorsements.